SIM
CRSP icon

Sonora Investment Management’s CRISPR Therapeutics CRSP Stock Holding History

Sonora Investment Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$21K Sell
190
-31
-14% -$3.89K ﹤0.01% 616
2021
Q2 		$36K Buy
221
+121
+121% +$14.7K ﹤0.01% 454
2021
Q1 		$12K Sell
100
-45
-31% -$6.79K ﹤0.01% 1163
2020
Q4 		$22K Hold
145
– – ﹤0.01% 879
2020
Q3 		$12K Hold
145
– – ﹤0.01% 1090
2020
Q2 		$11K Hold
145
– – ﹤0.01% 1040
2020
Q1 		$6K Buy
145
+45
+45% +$2.32K ﹤0.01% 1207
2019
Q4 		$6K Hold
100
– – ﹤0.01% 1342
2019
Q3 		$4K Hold
100
– – ﹤0.01% 1451
2019
Q2 		$5K Hold
100
– – ﹤0.01% 1372
2019
Q1 		$4K Buy
+100
New +$3.46K ﹤0.01% 1287
2018
Q3 		– Sell
-50
Closed -$3K – 1218
2018
Q2 		$3K Buy
+50
New +$2.85K ﹤0.01% 1021

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Sonora Investment Management's CRSP Position: Q3 2021 in Review

Sonora Investment Management reduced its CRISPR Therapeutics (CRSP) stake by 14% in Q3 2021, selling an estimated $3.89K and leaving 190 shares worth $21K. The position accounts for ﹤0.01% of the portfolio, ranked #616.

Sonora Investment Management first reported a position in CRSP in Q2 2018 and has held it in 12 quarters since. The position peaked at $36K in Q2 2021. 473 funds tracked by Wall St. Rank hold CRSP as of Q3 2021.

  • Sonora Investment Management held 190 shares of CRISPR Therapeutics worth $21K as of Q3 2021.
  • Sonora Investment Management sold 31 CRISPR Therapeutics shares in Q3 2021, an estimated $3.89K.
  • CRISPR Therapeutics made up ﹤0.01% of Sonora Investment Management's portfolio in Q3 2021, its #616 holding.
  • Sonora Investment Management first reported a position in CRISPR Therapeutics in Q2 2018 and has held it in 12 quarters since.
  • Sonora Investment Management's CRISPR Therapeutics position peaked at $36K in Q2 2021.
  • 473 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2021.

Based on Sonora Investment Management's 13F filing for Q3 2021, filed 12 Nov 2021.